Document is current
Any future updates will be listed below
-
Authors
Woelfle, Joachim https://orcid.org/0000-0002-9132-6174
Kreitschmann-Andermahr, I.
Strasburger, C. J.
Pittrow, D. B.
Pausch, C.
Schnabel, D.
-
Funding
Funding for this research was provided by:
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 24 March 2025
Accepted: 30 June 2025
First Online: 23 July 2025
Declarations
:
: The registry materials (protocol, patient information and informed consent form (ICF), and other required documents) were approved by the primary ethics committee (Ethics Committee of the Physician Chamber Saxony EK-BR-8/22 − 1 dated 26 January 2022). Any site that joins the registry has to provide additional ethics approval, if required by their local institutions. Protocol amendments, if any, will be subject to the same requirements as the original protocol. Written informed consent is a prerequisite for patients to be eligible for documentation in the study.
: All patients or their caregivers have given consent for publication of their pseudonymised data in a pooled format. The manuscript does not contain any individual person’s data in any form.
: DS: received consultant and / or speaker fees from Ascendis, Biomarin, Kyowa Kirin, Merck/Serono, Novo Nordisk, Pfizer, Sandoz/Novartis.CS: received consultancy fees from NovoNordisk, Sandoz-Hexal/Novartis, Ascendis, Pfizer, Consilient Health, Crinetics and Ipsen.DP: received consultancy fees from Amgen, Aspen, Biogen, Daiichi Sankyo, Sanofi-Genzyme, Sandoz/Novartis and MSD.CP: has no competing interests.JW: received consultant and / or speaker fees from Ascendis, Biomarin, Merck/Serono, Novo Nordisk, Pfizer, Sandoz/Novartis.IKA: received consultant and/or speaker fees from Sandoz/Novartis, Novo Nordisk and Pfizer.
: BfArM Nr. NIS7492, DRKS registry DRKS00027394.
